Omnicare, Inc. (NYSE:OCR)
A geriatric pharmaceutical services company, which provides pharmaceuticals and related ancillary pharmacy services to long-term healthcare institutions. Operates in two business segments: Pharmacy Services and Contract Research Organization Services.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
think guidence could come in better than the street expects on PDP rates and restructuring
Recs
Operates in a naturally strong sector -- geriatric pharmaceutical services. People are living longer and increasing their reliance pharma to maintain quality of life. Reasonably strong financial condition. Stock close to 52-week low. PEG less than 1.
Recs
Undervalued because of rough stretch last year. Has everything in place to excel. Watch for possible negative regulatory environment and evidence of further customer retention issues.
Recs
regulatory issues appear to be clearing
increasing services available
Recs
STrong position to negotiate best contracts
Recs
will weather recent storm with ease
Recs
Recovery pick
Recs
Great Company - market leader in the institutional pharmacy arena. Customers are a captive audience and the aging population is sure to keep filling beds. Recent hiccups due to regulatory issues will pass. Reimbursements with Medicare may be a long-term issue, but Medicare will never allow these companies to fail.
Recs
I believe it has the ability to generate strong free cash flow as its earnings grow both organically and through acquisitions. Transition to Medicare D has been a disaster, which pushed the stock down excessively.
Recs
The U.S. isn't getting any younger and with the price of drugs someone has got to be making money. Why not Omnicare?
Recs
Fair value price of 45.00.
Recs
Roll up story is done. Core operating ability is weak.
Recs
OCR has a domionant position in the supply of pahrmaceuticals to nursing homes. Presently they are being investigated for fraud, but over the long term, demographics will yield superior sales and income growth
Recs
This pharmcacy distributor specializes in nursing homes. Recommended by IV and then sold by IV for close to 100% gain. Has now dropped into mildy undervalued range. Expect 20% appreciation over next year.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 21 - 34 of 34 : « Previous 1 2